Share This Page
Drug Price Trends for ZELSUVMI
✉ Email this page to a colleague
Average Pharmacy Cost for ZELSUVMI
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ZELSUVMI 10.3% GEL | 83787-0103-31 | 61.85236 | GM | 2026-07-22 |
| ZELSUVMI 10.3% GEL | 83787-0103-31 | 61.88835 | GM | 2026-06-17 |
| ZELSUVMI 10.3% GEL | 83787-0103-31 | 61.83768 | GM | 2026-05-20 |
| ZELSUVMI 10.3% GEL | 83787-0103-31 | 61.56253 | GM | 2026-01-01 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
ZELSUVMI market analysis, pricing projections, and exclusivity risk for FDA-listed indications
Zelsuvmi is a photodynamic therapy product for actinic keratosis (AK) and is priced as a dermatology branded drug with reimbursement driven by site-of-care, payer clinical criteria, and prior authorization patterns. A complete, quantified market model (addressable patient counts, expected share by payer segment, realized net price, and NDC-level ASP history) and precise price projections cannot be produced from the information provided.
What is ZELSUVMI, and where is it used in dermatology treatment pathways?
Zelsuvmi is used in dermatology for actinic keratosis, a precancerous condition driven by cumulative UV exposure. Commercial uptake depends on:
- Clinical positioning versus cryotherapy, topical field therapies, and existing photodynamic therapy options
- Prescriber adoption of photodynamic workflow (light source setup, administration time, patient counseling)
- Payer coverage and step edits for AK severity, lesion count, and prior failures
How does Zelsuvmi compare with competing actinic keratosis therapies?
Key competitive sets typically include:
- Cryotherapy (lesion-directed)
- Topical field therapies (response depends on tolerability and lesion coverage)
- Existing photodynamic therapy regimens (brand and generic depending on formulation and light-activation approach)
Zelsuvmi’s share gain potential is tied to whether payers view it as clinically preferred or cost-effective relative to standard-of-care, and whether it reduces total treatment burden (visit count, treatment cycles, lesion clearance rate durability).
What is the Orange Book status of ZELSUVMI, and what patents protect it?
A market and legal risk analysis requires Orange Book patent listings (drug substance, drug product, method-of-use) and FDA reference-listed drug (RLD) mapping. No Orange Book status, patent numbers, or listed expiration dates are included in the input, so the protected IP landscape cannot be stated.
What is the patent expiration timeline for ZELSUVMI?
A price projection that accounts for generic/“authorized generic” or competing entry risk requires:
- Patent-by-patent expiration dates
- Any regulatory exclusivities (for example, 3-year/5-year/7-year exclusivity where applicable)
- Expected generic entry timing based on Paragraph IV certifications or settlement terms
No such dates are available in the input, so exclusivity timelines cannot be quantified.
When does ZELSUVMI lose exclusivity, and what generic entry risks exist?
Exclusivity and generic entry timing are the biggest drivers of mid-term price erosion in branded dermatology products. This requires:
- FDA exclusivity end date
- Orange Book legal status
- Litigation outcomes or settlements that delay entry
No legal status, exclusivity period end date, or litigation detail is provided, so entry risk cannot be translated into a price-erosion schedule.
What patent litigation affects ZELSUVMI pricing and competitive entry?
Price projections need the Paragraph IV and district court/CAFC record when available, including:
- Case captions and Docket numbers
- Filed theories and asserted patents
- Settlement agreements that include “at-risk” entry dates or monetary terms
No litigation record is included in the input.
What is ZELSUVMI’s FDA regulatory status and reimbursement profile?
A credible commercial model needs:
- FDA approval date and labeled regimen details
- Whether Zelsuvmi is reimbursed under J-codes/administration codes vs drug-only reimbursement
- Coverage determinations and utilization management (prior authorization, quantity limits)
- Consistency across Medicare and private payers
No FDA regulatory timeline or reimbursement coding detail is provided in the input, so pricing projections tied to adoption barriers cannot be grounded.
How many patients could use ZELSUVMI, and what is the addressable market size?
A price projection needs at least a scenario-based patient TAM/SAM model:
- AK prevalence treated in outpatient dermatology
- Eligible lesion count or clinical criteria aligned to labeling
- Proportion of patients receiving photodynamic therapy vs field therapy vs lesion-directed therapy
- Expected conversion rate from current standard-of-care
No epidemiology, eligible rate, or adoption assumption inputs are supplied, so TAM cannot be quantified.
What sales trajectory is realistic for ZELSUVMI under different adoption scenarios?
A market projection requires:
- Baseline realized net price, channel mix, and patient support programs
- Expected share by specialty (dermatology clinics vs academic vs hospital outpatient)
- Competitive response (pricing, contracting, alternative regimens)
None of these commercialization inputs are included.
What NDC-level pricing and net price assumptions drive ZELSUVMI revenue?
Branded drug revenue projection is sensitive to:
- Wholesale acquisition cost (WAC)
- Average sales price (ASP) and rebates
- Contract coverage in major pharmacy and specialty channels
- Patient assistance and copay card contribution
- Timing of price increases (if any) and payer discounting
The input provides no NDC, WAC/ASP, or contract rebate data, so net price cannot be modeled.
How strong is the patent estate for ZELSUVMI versus close photodynamic comparators?
A strength assessment requires patent family mapping and claim scope analysis tied to:
- Drug substance and activation chemistry
- Formulation and excipients
- Method-of-use (light parameters, dosing schedule, lesion selection)
- Manufacturing and process claims
No patent numbers or families are included, so the comparative strength cannot be evaluated.
What formulations are protected by ZELSUVMI patents, and does that affect generic risk?
Generic entry risk depends on whether protection is:
- Composition-of-matter (harder to design around)
- Formulation/process (may be partially design-around capable)
- Method-of-use only (often easier for competitors to pursue with different labeling, though labeling restrictions apply)
No formulation protection details are provided.
What generic launch scenarios exist for ZELSUVMI if exclusivity ends?
To define generic and authorized generic scenarios, a model needs:
- RLD reference
- Expected cost structure for generics
- Likely route of administration and device/light-source requirements
- Labeling restrictions tied to photodynamic activation protocols
No such details are included in the input.
Which companies are most likely to compete with ZELSUVMI?
A competitive list depends on:
- Photodynamic therapy incumbents and distributors
- Generic manufacturers with relevant capabilities
- Biosimilar-like analogs are not typical for small-molecule/derm photodynamic products, but competitors could include alternate AK field or light-activated products
No competitive set, company names, or marketed comparators are provided.
Key takeaways
- Zelsuvmi is positioned in actinic keratosis treatment within dermatology, with commercial outcomes tied to adoption of photodynamic workflow and payer clinical criteria.
- Quantified market sizing, addressable patient estimates, NDC-level realized net price, and time-based price erosion require data not provided in the input.
- Patent and exclusivity-driven price protection cannot be mapped without Orange Book and FDA legal status details, which are also not provided.
FAQs
- Is ZELSUVMI likely to face early biosimilar or generic substitution risk?
- Does ZELSUVMI pricing depend more on Medicare Part D or commercial rebate contracting?
- How do prior authorization requirements typically affect adoption of photodynamic AK therapies like ZELSUVMI?
- What contract structure (buy-and-bill vs pharmacy benefit) most commonly determines net price for dermatology drugs?
- How should investors model post-exclusivity price erosion for branded dermatology oncology-adjacent products?
References
No sources were provided in the input.
More… ↓
